Abstract:The National Occupational Research Agenda (NORA) was first established in 1996 by the National Institute for Occupational Safety and Health (NIOSH) and its partners as a framework to guide occupational safety and health research for the decade that followed. The process to develop NORA resulted in 21 research priorities, which can be found in the original document. NORA arose from the recognition that occupational safety and health research in both the public and the private sectors would benefit from targeting limited resources at important priorities. The creators of NORA also recognized the need to address changes in the workplace, as well as the increasingly diversified work force, in the United States. The distribution of jobs in the United States economy continues to shift from manufacturing to services. Longer hours, compressed work weeks, shift work, reduced job security, and part-time and temporary work are realities of the modern workplace. NORA continues to address the broadly recognized need to focus research in the areas with the highest likelihood of reducing the still significant toll of workplace injury and illness. Each day, an average of 9,000 workers in the United States sustain disabling injuries on the job, 16 die of injuries sustained at work, and 137 die of work-related diseases. The economic burden of this continuing toll is high. Data from a NIOSH-funded study reveal direct and indirect costs of occupational injuries and illnesses to be $171 billion annually ($145 billion for injuries and $26 billion for illnesses), compared with $33 billion for acquired immunodeficiency syndrome, $67.3 billion for Alzheimer’s disease, $164.3 billion for circulatory diseases, and $170.7 billion for cancer. Building on the success of NORA, development of the second decade of NORA began in 2005 and will use a sector-based approach. NIOSH and its partners will form eight Sector Research Councils (Figure), including participants from academia, industry, labor, and government. Each council will draft sector-based research goals, objectives, and action plans to provide guidance to the entire occupational safety and health community for moving research to practice in workplaces. In addition, a Cross-Sector Research Council will be formed to identify opportunities for common research across the sectors. Several town hall meetings are being conducted around the United States to help guide development of the second decade of NORA by gaining input from occupational safety and health stakeholders and partners, labor and employer groups, professional societies, academics, employers, workers, state and local public health officials, and elected officials. The goals of these meetings are to:

VEGF111b, a new member of VEGFxxxb isoforms and induced by mitomycin C, inhibits angiogenesis.

VEGF111b, a C-terminal splice variant of VEGF-A and induced by mitomycin C, inhibits ovarian cancer growth

VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway

Expression of VEGF(121) in Gastric Carcinoma MGC803 Cell Line.

The National Occupational Research Agenda—The Second Decade of NORA

A Vegfr1 Antagonistic Peptide Inhibits Tumor Growth and Metastasis Through Vegfr1-Pi3k-Akt Signaling Pathway Inhibition

Hvegf Sirna Inhibits Initial Growth of A549 Tumor Cells in Nude Mice and Angiogenesis on CAM Assay

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities

Interferon Alpha 2a Downregulates Vegf Expression Through Pi3 Kinase and Map Kinase Signaling Pathways

Characterization of Vascular Endothelial Growth Factor'S Effect on the Activation of Protein Kinase C, Its Isoforms, and Endothelial Cell Growth

MiR-181b suppresses angiogenesis by directly targeting cellular communication network factor 1

BML-111, the lipoxin A4 agonist, modulates VEGF or CoCl2-induced migration, angiogenesis and permeability in tumor-derived endothelial cells

Abstract 1356: Vascular Endothelial Growth Inhibitor - Potential Role in Targeted Therapy in Kidney Neoplasma Via Angiogenic Inhibition

Vascular Endothelial Growth Inhibitor in Human Cancer (Review)

A Novel Peptide Isolated from a Phage Display Library Inhibits Tumor Growth and Metastasis by Blocking the Binding of Vascular Endothelial Growth Factor to Its Kinase Domain Receptor.

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate

A Peptide Fusion Protein Inhibits Angiogenesis and Tumor Grow- Th by Blocking VEGF Binding to KDR

[Inhibition of K562 Cell Growth and Tumor Angiogenesis in Nude Mice by Antisense VEGF(121) Cdna Transfection].

Cs5931, A Novel Polypeptide In Ciona Savignyi, Represses Angiogenesis Via Inhibiting Vascular Endothelial Growth Factor (Vegf) And Matrix Metalloproteinases (Mmps)

[Inhibition of tumor growth by a peptide fusion protein binding to vascular endothelial growth factor receptor Flt-1]

The study of IGF-1 in stimulating expression of vascular endothelial growth factor-C in the breast cancer cell line MDA-MB-231